Rajesh Behl, MD
Hematology · Emeryville
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 33 years
- Graduated 1993
Offices
1 location · Epic Care · 54 clinicians in this group
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp · Contra Costa Regional Medical Center · John Muir Medical Center - Concord Campus · John Muir Medical Center - Walnut Creek Campus. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Behl’s office at (510) 629-6682 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Contra Costa Regional Medical CenterMartinez, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Contra Costa Health ServicesPatients rate it 3 of 5 · 73% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.167, Oct 2024 – Sep 2025
- John Muir Medical Center - Concord CampusConcord, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.235, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.675, Oct 2024 – Sep 2025
- John Muir Medical Center - Walnut Creek CampusWalnut Creek, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 2.01 (1.17 to 2.85) · 2,206 cases, Jul 2022 – Jun 2024Worse than the national rate — Death rate among surgical inpatients with serious treatable complications: 222.42 (177.82 to 267.02) · 120 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.4 (0.91 to 1.9) · 9,764 cases, Jul 2022 – Jun 2024Worse than the national rate — SSI - Colon Surgery: 2.734, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.536, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.341, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.455, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.245, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Contra Costa Regional Medical Center
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 1 better, 4 the same, 1 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.167 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0 to 2.04) · 188 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.08 (0.63 to 1.53) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.8 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 114 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.3 · 27 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 321 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.44) · 1,181 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.47) · 1,198 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.2 (0.67 to 5.72) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 71 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.5 (0.82 to 4.18) · 195 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.36 (1.01 to 19.71) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.08) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.07 (0.55 to 3.58) · 67 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.93 (0 to 2.03) · 981 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.948 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 2.027 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.3 · 101 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 52.2 · 126 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -53.6 · 112 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 87 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.7 to 8.6) · 95 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (8.8 to 17.8) · 95 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 35 cases | None | Jul 2023 – Jun 2025 |
What patients said (521 patients answered, 10% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 79% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 78% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 54% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for John Muir Medical Center - Concord Campus
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.235 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.675 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.11 (0.21 to 2) · 1,612 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.77 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 184.13 (136.65 to 231.6) · 86 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.2 · 175 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.6 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.4 · 172 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8 · 537 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.5 · 434 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13 · 215 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,208 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.32 (0.13 to 0.51) · 7,626 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.04 to 0.41) · 8,660 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.1 (1.29 to 4.91) · 2,723 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.21 (0 to 2.51) · 1,208 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3 (1.7 to 4.3) · 2,355 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.77 (3.24 to 12.3) · 1,216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.43 (0.43 to 6.43) · 1,253 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.93 (0.47 to 3.4) · 388 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.14 (0.58 to 1.69) · 6,288 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 263 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.636 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.254 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.904 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.5 · 312 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.1 · 768 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -6.8 · 295 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.1 · 648 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 31.1 · 433 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 504 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (5.1 to 8.8) · 476 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.9 (10.5 to 15.7) · 476 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 8.8 · 154 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.7 · 186 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (9.9 to 17.9) · 192 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.2) · 546 cases | No different | Jan 2024 – Dec 2024 |
What patients said (521 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for John Muir Medical Center - Walnut Creek Campus
Behind the star rating — Deaths: 3 better, 2 the same, 2 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 3 better, 5 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 2.01 (1.17 to 2.85) · 2,206 cases | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 222.42 (177.82 to 267.02) · 120 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.4 (0.91 to 1.9) · 9,764 cases | Worse | Jul 2022 – Jun 2024 |
| SSI - Colon SurgeryInfections | 2.734 | Worse | Oct 2024 – Sep 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.536 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.341 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.455 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.245 | Better | Oct 2024 – Sep 2025 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.87 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 131 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 695 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.5 · 827 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.1 · 509 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 4,483 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.35 (0.18 to 0.53) · 11,630 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.05 to 0.39) · 11,793 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.69 to 4.96) · 3,268 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.37 (0 to 2.94) · 1,631 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.76 (1.43 to 4.09) · 3,066 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.12 (0.22 to 12.02) · 1,580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.43 (1.21 to 7.64) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 685 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 615 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.88 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 93 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 729 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.1 · 91 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13 · 736 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 34.8 · 842 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 818 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.4) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.2 to 15.5) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 584 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 139 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.9) · 222 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 321 cases | No different | Jan 2024 – Dec 2024 |
What patients said (758 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$224,422
Medicare paid this office $224,422 for 537 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 420 | $90,938 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $47,822 | $105 |
| Long return visit (40+ min) | 119 | $39,759 | $121 |
| Short return visit (20+ min) | 105 | $9,648 | $55 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 224 | $9,315 | $15 |
See all 10 services
| Return visit (30+ min) | 420 | $90,938 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $47,822 | $105 |
| Long return visit (40+ min) | 119 | $39,759 | $121 |
| Short return visit (20+ min) | 105 | $9,648 | $55 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 224 | $9,315 | $15 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $7,820 | $150 |
| New patient visit (60+ min) | 33 | $4,600 | $139 |
| Mechanical separation of red blood cells from blood | 11 | $3,727 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $3,361 | $70 |
| Biopsy of bone marrow | 35 | $2,608 | $64 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of bone marrow | 81 | 75 | 72 | 62 | 73 | 41 |
| Mechanical separation of red blood cells from blood | – | – | 51 | – | 40 | 42 |
| Biopsy and aspiration of bone marrow sample for diagnosis | – | – | – | 13 | 15 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
537 Original Medicare patients in 2024. Average age 76 · Under 65 7% · 85 and older 20% · Women 48% · Also on Medicaid 21% · Health risk score 2.23. At or below the middle of the specialty; the typical hematology clinician is at 2.35.
Conditions among them: High blood pressure 68% · Chronic kidney disease 37% · Diabetes 30% · Coronary heart disease 23% · Cancer 21% · Atrial fibrillation 21% · Heart failure 18% · Depression 18% · COPD 11% · Stroke 10% · Dementia 8%.
The office billed $1,034,225, Medicare allowed $300,552 and paid $224,422; for 3,020 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 537 | 3,020 | 76 | 2.23 | $1,034,225 | $224,422 |
| 2023 | 581 | 2,969 | 76 | 2.07 | $1,168,974 | $271,199 |
| 2022 | 577 | 3,072 | 76 | 2.07 | $1,175,671 | $270,994 |
| 2021 | 615 | 3,134 | 75 | 2.17 | $1,221,799 | $271,011 |
| 2020 | 621 | 3,398 | 75 | 2.28 | $1,447,368 | $255,637 |
| 2019 | 634 | 3,356 | 75 | 2.25 | $1,267,212 | $237,910 |
| 2018 | 611 | 3,549 | 74 | 2.33 | $1,458,993 | $256,762 |
| 2017 | 547 | 3,046 | 74 | 2.33 | $1,197,250 | $219,989 |
| 2016 | 460 | 2,575 | 73 | 2.21 | $1,012,290 | $177,810 |
| 2015 | 434 | 2,342 | 73 | 2.09 | $830,462 | $164,324 |
| 2014 | 367 | 2,024 | 73 | 2.11 | $697,587 | $130,636 |
| 2013 | 326 | 1,864 | 73 | 2.08 | $635,318 | $125,895 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Return visit (30+ min) | 404 | $103,414 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 86 | $65,066 | $108 |
| Long return visit (40+ min) | 146 | $43,463 | $124 |
| Short return visit (20+ min) | 212 | $18,396 | $53 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $11,511 | $158 |
| New patient visit (45+ min) | 48 | $5,546 | $116 |
| New patient visit (60+ min) | 33 | $5,065 | $153 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $4,935 | $73 |
| Mechanical separation of red blood cells from blood | 13 | $3,726 | $93 |
| Biopsy of bone marrow | 52 | $3,556 | $59 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 15 | $1,033 | $69 |
| Biopsy of bone marrow | 11 | $841 | $65 |
2022: 12 services
| Return visit (30+ min) | 410 | $100,873 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 107 | $75,464 | $93 |
| Long return visit (40+ min) | 139 | $34,078 | $127 |
| Short return visit (20+ min) | 196 | $16,555 | $54 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $14,067 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 40 | $7,079 | $65 |
| New patient visit (60+ min) | 28 | $3,963 | $142 |
| New patient visit (45+ min) | 36 | $3,889 | $108 |
| Biopsy of bone marrow | 39 | $2,848 | $62 |
| Hospital discharge day management, more than 30 minutes | 11 | $2,606 | $97 |
| Biopsy of bone marrow | 14 | $1,040 | $65 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 13 | $952 | $73 |
2021: 12 services
| Return visit (30+ min) | 393 | $106,444 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 116 | $58,105 | $93 |
| Long return visit (40+ min) | 123 | $31,605 | $128 |
| Short return visit (20+ min) | 266 | $27,824 | $54 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 62 | $14,812 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 54 | $6,251 | $65 |
| Mechanical separation of red blood cells from blood | 11 | $4,800 | $94 |
| New patient visit (45+ min) | 37 | $4,102 | $111 |
| New patient visit (60+ min) | 23 | $3,832 | $167 |
| Biopsy of bone marrow | 53 | $3,431 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,961 | $123 |
| Biopsy of bone marrow | 15 | $1,037 | $65 |
2020: 12 services
| Return visit (30+ min) | 431 | $86,520 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 113 | $68,804 | $96 |
| Long return visit (40+ min) | 129 | $28,098 | $99 |
| Short return visit (20+ min) | 229 | $24,791 | $45 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 66 | $9,140 | $67 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $7,938 | $180 |
| New patient visit (60+ min) | 43 | $6,077 | $141 |
| New patient visit (45+ min) | 44 | $4,822 | $110 |
| Biopsy of bone marrow | 49 | $3,607 | $66 |
| Biopsy of bone marrow | 17 | $1,320 | $66 |
| Short return visit | 21 | $729 | $23 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $527 | $44 |
2019: 14 services
| Return visit (30+ min) | 430 | $86,145 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 135 | $67,749 | $93 |
| Short return visit (20+ min) | 219 | $22,841 | $42 |
| Long return visit (40+ min) | 102 | $18,027 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 72 | $14,034 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $4,923 | $182 |
| Biopsy of bone marrow | 60 | $4,240 | $64 |
| New patient visit (30+ min) | 43 | $2,740 | $64 |
| New patient visit (45+ min) | 27 | $2,716 | $101 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,599 | $114 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,445 | $90 |
| Biopsy of bone marrow | 14 | $939 | $63 |
| New patient visit (15+ min) | 21 | $870 | $41 |
| Short return visit | 19 | $574 | $21 |
2018: 19 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 110 | $70,221 | $93 |
| Return visit (30+ min) | 379 | $63,459 | $69 |
| Return visit (30+ min) | 235 | $18,871 | $50 |
| Short return visit (20+ min) | 169 | $18,699 | $45 |
| Long return visit (40+ min) | 89 | $14,117 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $10,731 | $173 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 58 | $9,637 | $65 |
| New patient visit (60+ min) | 45 | $6,561 | $146 |
| Long return visit (40+ min) | 63 | $6,221 | $80 |
| Short return visit (20+ min) | 85 | $5,394 | $36 |
| New patient visit (60+ min) | 25 | $3,153 | $126 |
| Biopsy of bone marrow | 47 | $3,082 | $64 |
| New patient visit (45+ min) | 23 | $2,582 | $112 |
| Biopsy of bone marrow | 39 | $2,473 | $58 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 21 | $2,134 | $89 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,935 | $121 |
| Administration of chemotherapy into fluid-filled space between the tissue that cover the brain and spinal cord | 11 | $1,436 | $72 |
| Short return visit | 34 | $1,149 | $23 |
| Short return visit | 19 | $495 | $17 |
2017: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 108 | $67,592 | $91 |
| Return visit (30+ min) | 350 | $64,053 | $64 |
| Short return visit (20+ min) | 215 | $25,213 | $43 |
| Long return visit (40+ min) | 115 | $18,032 | $94 |
| New patient visit (60+ min) | 68 | $9,921 | $146 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $9,752 | $171 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 42 | $5,566 | $63 |
| Biopsy of bone marrow | 62 | $4,346 | $65 |
| Short return visit | 51 | $1,835 | $21 |
| New patient visit (45+ min) | 16 | $1,706 | $107 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,669 | $119 |
2016: 12 services
| Return visit (30+ min) | 307 | $61,920 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 92 | $48,185 | $88 |
| Short return visit (20+ min) | 184 | $18,635 | $41 |
| Long return visit (40+ min) | 64 | $9,426 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,847 | $171 |
| New patient visit (60+ min) | 50 | $6,799 | $136 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $6,281 | $62 |
| Biopsy of bone marrow | 60 | $4,260 | $64 |
| New patient visit (45+ min) | 30 | $3,011 | $100 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,589 | $93 |
| Short return visit | 41 | $1,443 | $21 |
| Administration of chemotherapy into fluid-filled space between the tissue that cover the brain and spinal cord | 12 | $1,079 | $67 |
2015: 11 services
| Return visit (30+ min) | 308 | $56,779 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 80 | $49,667 | $88 |
| Short return visit (20+ min) | 185 | $16,454 | $42 |
| Long return visit (40+ min) | 72 | $10,351 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $6,161 | $171 |
| New patient visit (45+ min) | 47 | $4,695 | $100 |
| Biopsy of bone marrow | 58 | $3,817 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $3,365 | $61 |
| New patient visit (60+ min) | 20 | $2,837 | $142 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,614 | $115 |
| Short return visit | 36 | $1,112 | $21 |
2014: 9 services
| Return visit (30+ min) | 262 | $59,915 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 70 | $28,963 | $88 |
| Short return visit (20+ min) | 129 | $16,138 | $41 |
| Long return visit (40+ min) | 52 | $8,240 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,577 | $170 |
| New patient visit (60+ min) | 20 | $2,833 | $142 |
| Biopsy of bone marrow | 35 | $2,741 | $65 |
| New patient visit (45+ min) | 22 | $1,974 | $90 |
| Short return visit | 35 | $1,128 | $21 |
2013: 10 services
| Return visit (30+ min) | 236 | $48,762 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $34,393 | $86 |
| Short return visit (20+ min) | 101 | $11,288 | $39 |
| Long return visit (40+ min) | 52 | $8,867 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $5,514 | $167 |
| New patient visit (45+ min) | 51 | $5,327 | $104 |
| Biopsy of bone marrow | 50 | $3,224 | $62 |
| New patient visit (60+ min) | 16 | $2,100 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,374 | $60 |
| Short return visit | 22 | $780 | $20 |
Medicaid work
$1,921 in 2024
Medicaid paid $1,921 for 154 billed services this clinician did in 2024, up to 27 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 154 | $1,921 |
| 2024 | 154 | 1 | 27 | $1,921 |
| 2023 | 176 | 4 | 25 | $1,288 |
| 2022 | 355 | 7 | 21 | $1,973 |
| 2021 | 1,009 | 8 | 28 | $4,312 |
| 2020 | 772 | 7 | 21 | $1,503 |
| 2019 | 501 | 6 | 28 | $1,190 |
| 2018 | 480 | 7 | 26 | $578 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 123 | $1,156 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 20 | $68 |
| COMPREHENSIVE METABOLIC PANEL | 17 | $64 |
| Hospital outpatient clinic visit for assessment and management of a patient | 16 | $0 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 41 | $1,175 |
| Return visit (30+ min) | 79 | $604 |
| COMPREHENSIVE METABOLIC PANEL | 29 | $79 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 45 | $78 |
| Lactate dehydrogenase (LD), (LDH) | 28 | $37 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 30 | $0 |
| Hospital outpatient clinic visit for assessment and management of a patient | 103 | $0 |
2021
| Return visit (30+ min) | 246 | $3,039 |
| COMPREHENSIVE METABOLIC PANEL | 191 | $549 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 41 | $361 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 169 | $260 |
| Short return visit (20+ min) | 16 | $66 |
| Lactate dehydrogenase (LD), (LDH) | 74 | $38 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 50 | $0 |
| Hospital outpatient clinic visit for assessment and management of a patient | 222 | $0 |
2020
| Return visit (30+ min) | 192 | $897 |
| COMPREHENSIVE METABOLIC PANEL | 158 | $274 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 134 | $226 |
| Hospital outpatient clinic visit for assessment and management of a patient | 212 | $49 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 32 | $46 |
| Lactate dehydrogenase (LD), (LDH) | 15 | $11 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 29 | $0 |
2019
| COMPREHENSIVE METABOLIC PANEL | 77 | $619 |
| Return visit (30+ min) | 92 | $525 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 82 | $38 |
| Lactate dehydrogenase (LD), (LDH) | 31 | $8 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 13 | $0 |
| Hospital outpatient clinic visit for assessment and management of a patient | 206 | $0 |
2018
| Return visit (30+ min) | 90 | $393 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 125 | $97 |
| Short return visit (20+ min) | 17 | $65 |
| COMPREHENSIVE METABOLIC PANEL | 79 | $24 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 38 | $0 |
| Lactate dehydrogenase (LD), (LDH) | 17 | $0 |
| Hospital outpatient clinic visit for assessment and management of a patient | 114 | $0 |
Drugs they prescribed that Part D paid
$9,301,317
Pharmacies billed $9,301,317 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,223 generic and 661 brand-name prescriptions · $9,301,317 in drug cost · 115 antibiotic prescriptions to 41 people · 27 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Revlimid | 73 | $1,477,689 | $20,242 |
| Jakafi | 77 | $1,438,553 | $18,683 |
| Xpovio | 43 | $1,282,121 | $29,817 |
| Lenalidomide | 76 | $1,217,848 | $16,024 |
| Imbruvica | 47 | $723,819 | $15,400 |
See all 36 drugs
| Revlimid | 73 | $1,477,689 | $20,242 |
| Jakafi | 77 | $1,438,553 | $18,683 |
| Xpovio | 43 | $1,282,121 | $29,817 |
| Lenalidomide | 76 | $1,217,848 | $16,024 |
| Imbruvica | 47 | $723,819 | $15,400 |
| Brukinsa | 31 | $457,057 | $14,744 |
| Venclexta | 58 | $410,821 | $7,083 |
| Calquence | 26 | $399,828 | $15,378 |
| Ojjaara | 14 | $375,754 | $26,840 |
| Iclusig | 12 | $257,383 | $21,449 |
| Scemblix | 17 | $213,075 | $12,534 |
| Promacta | 15 | $194,496 | $12,966 |
| Xarelto | 79 | $89,619 | $1,134 |
| Eliquis | 70 | $52,675 | $752 |
| Varubi | 33 | $42,871 | $1,299 |
| Posaconazole | 11 | $24,630 | $2,239 |
| Imatinib Mesylate | 22 | $8,735 | $397 |
| Acyclovir | 340 | $5,845 | $17 |
| Atovaquone | 21 | $3,886 | $185 |
| Dexamethasone | 114 | $2,379 | $21 |
| Hydroxyurea | 102 | $2,251 | $22 |
| Entecavir | 23 | $1,131 | $49 |
| Fluconazole | 22 | $845 | $38 |
| Prochlorperazine Maleate | 53 | $693 | $13 |
| Potassium Chloride | 34 | $616 | $18 |
| Ondansetron | 42 | $534 | $13 |
| Sulfamethoxazole-Trimethoprim | 55 | $211 | $4 |
| Allopurinol | 11 | $184 | $17 |
| Olanzapine | 29 | $177 | $6 |
| Warfarin | 12 | $162 | $14 |
| Gabapentin | 33 | $141 | $4 |
| Cephalexin | 11 | $122 | $11 |
| Pantoprazole | 13 | $97 | $7 |
| Amlodipine Besylate | 11 | $74 | $7 |
| Azithromycin | 15 | $48 | $3 |
| Famotidine | 12 | $43 | $4 |
Year by year
| 2024 | 1,884 | 185 | None | 35% | $9,301,317 |
| 2023 | 1,855 | 195 | None | None | $7,214,238 |
| 2022 | 1,763 | 191 | None | None | $8,082,111 |
| 2021 | 1,981 | 174 | None | None | $8,363,329 |
| 2020 | 1,674 | 171 | None | None | $6,446,194 |
| 2019 | 1,416 | 156 | 2% (29) | 43% | $5,040,960 |
| 2018 | 1,508 | 160 | 5% (68) | 31% | $3,898,467 |
| 2017 | 1,243 | 154 | 6% (70) | 21% | $2,195,848 |
| 2016 | 1,094 | 130 | 6% (69) | 23% | $2,229,373 |
| 2015 | 860 | 106 | 5% (45) | None | $1,523,396 |
| 2014 | 982 | 116 | 7% (73) | None | $1,185,258 |
| 2013 | 980 | 104 | 6% (61) | 19% | $1,234,290 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 37 drugs
| Revlimid | 76 | $1,600,523 | $21,060 |
| Jakafi | 73 | $1,436,927 | $19,684 |
| Lenalidomide | 67 | $1,166,649 | $17,413 |
| Imbruvica | 30 | $510,356 | $17,012 |
| Venclexta | 91 | $407,030 | $4,473 |
| Calquence | 25 | $380,579 | $15,223 |
| Xpovio | 12 | $318,810 | $26,567 |
| Iclusig | 12 | $243,444 | $20,287 |
| Brukinsa | 11 | $154,614 | $14,056 |
| Promacta | 11 | $142,664 | $12,969 |
| Xarelto | 112 | $107,637 | $961 |
| Posaconazole | 38 | $91,349 | $2,404 |
| Scemblix | 12 | $82,952 | $6,913 |
| Eliquis | 60 | $46,065 | $768 |
| Aminocaproic Acid | 12 | $20,004 | $1,667 |
| Entecavir | 13 | $13,450 | $1,035 |
| Imatinib Mesylate | 24 | $7,838 | $327 |
| Acyclovir | 283 | $5,990 | $21 |
| Potassium Chloride | 56 | $2,440 | $44 |
| Hydroxyurea | 81 | $2,425 | $30 |
| Fluconazole | 51 | $2,156 | $42 |
| Colesevelam | 11 | $2,025 | $184 |
| Dexamethasone | 90 | $1,778 | $20 |
| Dapsone | 21 | $1,165 | $55 |
| Gabapentin | 49 | $673 | $14 |
| Prochlorperazine Maleate | 48 | $605 | $13 |
| Ondansetron | 18 | $320 | $18 |
| Cephalexin | 12 | $298 | $25 |
| Sulfamethoxazole-Trimethoprim | 44 | $291 | $7 |
| Allopurinol | 20 | $283 | $14 |
| Pantoprazole | 17 | $281 | $17 |
| Warfarin | 14 | $232 | $17 |
| Levofloxacin | 17 | $216 | $13 |
| Ondansetron Odt | 12 | $213 | $18 |
| Nystatin | 12 | $154 | $13 |
| Azithromycin | 21 | $93 | $4 |
| Amoxicillin | 11 | $12 | $1 |
2022: 36 drugs
| Revlimid | 144 | $3,167,388 | $21,996 |
| Jakafi | 59 | $1,148,892 | $19,473 |
| Venclexta | 102 | $971,142 | $9,521 |
| Xpovio | 19 | $461,689 | $24,299 |
| Calquence | 30 | $451,054 | $15,035 |
| Promacta | 19 | $350,590 | $18,452 |
| Imbruvica | 24 | $312,933 | $13,039 |
| Iclusig | 12 | $225,407 | $18,784 |
| Ninlaro | 15 | $170,755 | $11,384 |
| Xarelto | 131 | $120,977 | $923 |
| Posaconazole | 15 | $63,255 | $4,217 |
| Eliquis | 57 | $38,160 | $669 |
| Voriconazole | 13 | $6,360 | $489 |
| Imatinib Mesylate | 17 | $5,871 | $345 |
| Acyclovir | 243 | $5,521 | $23 |
| Hydroxyurea | 93 | $3,319 | $36 |
| Fluconazole | 44 | $1,928 | $44 |
| Dexamethasone | 82 | $1,913 | $23 |
| Entecavir | 11 | $1,880 | $171 |
| Dapsone | 28 | $1,593 | $57 |
| Potassium Chloride | 27 | $1,141 | $42 |
| Prochlorperazine Maleate | 50 | $764 | $15 |
| Ondansetron | 27 | $444 | $16 |
| Gabapentin | 19 | $367 | $19 |
| Pantoprazole | 29 | $310 | $11 |
| Amlodipine Besylate | 20 | $229 | $11 |
| Lidocaine Hcl Viscous | 20 | $204 | $10 |
| Allopurinol | 20 | $163 | $8 |
| Sulfamethoxazole-Trimethoprim | 36 | $143 | $4 |
| Nystatin | 14 | $120 | $9 |
| Levofloxacin | 12 | $87 | $7 |
| Folic Acid | 14 | $80 | $6 |
| Azithromycin | 12 | $67 | $6 |
| Warfarin | 16 | $54 | $3 |
| Cephalexin | 14 | $51 | $4 |
| Furosemide | 11 | $17 | $2 |
2021: 40 drugs
| Revlimid | 144 | $2,819,480 | $19,580 |
| Jakafi | 49 | $872,494 | $17,806 |
| Imbruvica | 52 | $685,733 | $13,187 |
| Calquence | 46 | $679,576 | $14,773 |
| Venclexta | 90 | $662,822 | $7,365 |
| Ninlaro | 36 | $385,644 | $10,712 |
| Promacta | 11 | $370,863 | $33,715 |
| Iclusig | 11 | $193,515 | $17,592 |
| Kisqali | 12 | $179,552 | $14,963 |
| Brukinsa | 12 | $160,784 | $13,399 |
| Xarelto | 151 | $122,137 | $809 |
| Inqovi | 12 | $98,089 | $8,174 |
| Procrit | 16 | $73,003 | $4,563 |
| Eliquis | 44 | $32,903 | $748 |
| Deferasirox | 11 | $23,277 | $2,116 |
| Voriconazole | 20 | $15,737 | $787 |
| Imatinib Mesylate | 15 | $15,605 | $1,040 |
| Cyclosporine Modified | 21 | $5,886 | $280 |
| Retacrit | 12 | $5,665 | $472 |
| Acyclovir | 249 | $5,289 | $21 |
| Hydroxyurea | 118 | $3,766 | $32 |
| Dexamethasone | 103 | $2,635 | $26 |
| Potassium Chloride | 55 | $2,634 | $48 |
| Entecavir | 15 | $2,557 | $170 |
| Dapsone | 35 | $1,897 | $54 |
| Fluconazole | 39 | $1,583 | $41 |
| Prochlorperazine Maleate | 71 | $984 | $14 |
| Ondansetron | 36 | $552 | $15 |
| Pantoprazole | 27 | $393 | $15 |
| Letrozole | 12 | $374 | $31 |
| Allopurinol | 30 | $316 | $11 |
| Prednisone | 17 | $182 | $11 |
| Levofloxacin | 18 | $169 | $9 |
| Warfarin | 17 | $160 | $9 |
| Sulfamethoxazole-Trimethoprim | 39 | $150 | $4 |
| Tamsulosin | 11 | $147 | $13 |
| Amlodipine Besylate | 13 | $130 | $10 |
| Gabapentin | 13 | $94 | $7 |
| Cephalexin | 16 | $60 | $4 |
| Folic Acid | 11 | $47 | $4 |
2020: 35 drugs
| Imbruvica | 133 | $1,681,135 | $12,640 |
| Revlimid | 78 | $1,349,004 | $17,295 |
| Jakafi | 51 | $770,255 | $15,103 |
| Pomalyst | 28 | $523,334 | $18,691 |
| Ninlaro | 32 | $329,233 | $10,289 |
| Iclusig | 12 | $202,713 | $16,893 |
| Venclexta | 31 | $197,558 | $6,373 |
| Kisqali | 12 | $159,625 | $13,302 |
| Xarelto | 116 | $90,897 | $784 |
| Procrit | 13 | $50,329 | $3,871 |
| Eliquis | 49 | $28,286 | $577 |
| Imatinib Mesylate | 11 | $6,867 | $624 |
| Entecavir | 17 | $5,277 | $310 |
| Hydroxyurea | 114 | $4,806 | $42 |
| Acyclovir | 199 | $4,309 | $22 |
| Cyclosporine Modified | 11 | $2,241 | $204 |
| Dexamethasone | 69 | $1,884 | $27 |
| Fluconazole | 34 | $1,476 | $43 |
| Vancomycin | 14 | $1,401 | $100 |
| Prochlorperazine Maleate | 61 | $767 | $13 |
| Potassium Chloride | 49 | $709 | $14 |
| Ondansetron | 30 | $640 | $21 |
| Gabapentin | 21 | $450 | $21 |
| Allopurinol | 29 | $446 | $15 |
| Warfarin | 19 | $362 | $19 |
| Clarithromycin | 11 | $352 | $32 |
| Letrozole | 13 | $286 | $22 |
| Pantoprazole | 17 | $178 | $10 |
| Levofloxacin | 19 | $175 | $9 |
| Prednisone | 20 | $169 | $8 |
| Tamsulosin | 15 | $155 | $10 |
| Cephalexin | 14 | $86 | $6 |
| Nystatin | 11 | $84 | $8 |
| Sulfamethoxazole-Trimethoprim | 40 | $83 | $2 |
| Lidocaine Hcl Viscous | 11 | $74 | $7 |
2019: 29 drugs
| Imbruvica | 124 | $1,500,962 | $12,105 |
| Revlimid | 71 | $1,155,911 | $16,280 |
| Jakafi | 45 | $599,406 | $13,320 |
| Pomalyst | 24 | $427,753 | $17,823 |
| Iclusig | 14 | $253,388 | $18,099 |
| Ninlaro | 20 | $198,606 | $9,930 |
| Jadenu | 17 | $157,832 | $9,284 |
| Venclexta | 14 | $150,179 | $10,727 |
| Procrit | 36 | $104,432 | $2,901 |
| Xarelto | 91 | $68,039 | $748 |
| Eliquis | 54 | $26,501 | $491 |
| Hydroxyurea | 147 | $5,190 | $35 |
| Epogen | 12 | $4,258 | $355 |
| Acyclovir | 118 | $2,845 | $24 |
| Dexamethasone | 66 | $1,370 | $21 |
| Potassium Chloride | 53 | $981 | $19 |
| Fluconazole | 11 | $636 | $58 |
| Ondansetron | 29 | $594 | $20 |
| Hydrocodone-Acetaminophen | 25 | $562 | $22 |
| Allopurinol | 29 | $466 | $16 |
| Tamoxifen Citrate | 12 | $433 | $36 |
| Gabapentin | 28 | $383 | $14 |
| Prochlorperazine Maleate | 34 | $347 | $10 |
| Warfarin | 20 | $299 | $15 |
| Cephalexin | 17 | $113 | $7 |
| Azithromycin | 16 | $110 | $7 |
| Pantoprazole | 12 | $102 | $8 |
| Lidocaine Hcl Viscous | 11 | $87 | $8 |
| Prednisone | 11 | $86 | $8 |
2018: 33 drugs
| Imbruvica | 98 | $1,136,821 | $11,600 |
| Revlimid | 71 | $1,054,491 | $14,852 |
| Pomalyst | 23 | $378,752 | $16,467 |
| Ninlaro | 34 | $338,527 | $9,957 |
| Jakafi | 16 | $205,794 | $12,862 |
| Xarelto | 88 | $47,995 | $545 |
| Procrit | 14 | $45,071 | $3,219 |
| Entecavir | 16 | $13,346 | $834 |
| Eliquis | 23 | $10,876 | $473 |
| Hydroxyurea | 155 | $4,718 | $30 |
| Anagrelide | 16 | $2,893 | $181 |
| Acyclovir | 105 | $2,219 | $21 |
| Dexamethasone | 106 | $2,168 | $20 |
| Dutasteride | 11 | $1,614 | $147 |
| Warfarin | 58 | $1,401 | $24 |
| Hydrocodone-Acetaminophen | 55 | $1,305 | $24 |
| Potassium Chloride | 44 | $925 | $21 |
| Ketoconazole | 16 | $857 | $54 |
| Megestrol Acetate | 13 | $690 | $53 |
| Clarithromycin | 15 | $655 | $44 |
| Ondansetron | 31 | $634 | $20 |
| Fluconazole | 13 | $544 | $42 |
| Tamoxifen Citrate | 14 | $510 | $36 |
| Pantoprazole | 30 | $439 | $15 |
| Famciclovir | 14 | $435 | $31 |
| Prochlorperazine Maleate | 33 | $384 | $12 |
| Allopurinol | 24 | $290 | $12 |
| Gabapentin | 19 | $231 | $12 |
| Tamsulosin | 12 | $169 | $14 |
| Cephalexin | 18 | $168 | $9 |
| Lorazepam | 31 | $149 | $5 |
| Azithromycin | 16 | $109 | $7 |
| Omeprazole | 17 | $104 | $6 |
2017: 24 drugs
| Revlimid | 65 | $704,785 | $10,843 |
| Imbruvica | 46 | $468,748 | $10,190 |
| Pomalyst | 11 | $161,139 | $14,649 |
| Xarelto | 41 | $17,842 | $435 |
| Entecavir | 13 | $9,768 | $751 |
| Creon | 12 | $8,452 | $704 |
| Hydroxyurea | 117 | $3,592 | $31 |
| Danazol | 15 | $2,813 | $188 |
| Warfarin | 113 | $2,256 | $20 |
| Acyclovir | 109 | $1,692 | $16 |
| Hydrocodone-Acetaminophen | 50 | $1,313 | $26 |
| Dexamethasone | 62 | $1,220 | $20 |
| Ondansetron | 41 | $584 | $14 |
| Megestrol Acetate | 15 | $550 | $37 |
| Potassium Chloride | 38 | $479 | $13 |
| Famciclovir | 13 | $441 | $34 |
| Ketoconazole | 11 | $382 | $35 |
| Diphenoxylate-Atropine | 13 | $267 | $21 |
| Prochlorperazine Maleate | 49 | $245 | $5 |
| Lorazepam | 53 | $186 | $4 |
| Prednisone | 13 | $130 | $10 |
| Cephalexin | 16 | $107 | $7 |
| Azithromycin | 18 | $90 | $5 |
| Allopurinol | 11 | $87 | $8 |
2016: 28 drugs
| Revlimid | 78 | $804,625 | $10,316 |
| Imbruvica | 49 | $505,481 | $10,316 |
| Pomalyst | 11 | $133,864 | $12,169 |
| Entecavir | 12 | $10,255 | $855 |
| Xarelto | 19 | $9,050 | $476 |
| Creon | 14 | $7,514 | $537 |
| Enoxaparin | 11 | $4,330 | $394 |
| Famciclovir | 13 | $3,193 | $246 |
| Hydrocodone-Acetaminophen | 60 | $2,034 | $34 |
| Warfarin | 140 | $2,011 | $14 |
| Acyclovir | 89 | $1,817 | $20 |
| Hydroxyurea | 84 | $1,611 | $19 |
| Fluconazole | 30 | $1,407 | $47 |
| Dexamethasone | 34 | $797 | $23 |
| Ondansetron | 26 | $483 | $19 |
| Megestrol Acetate | 13 | $388 | $30 |
| Potassium Chloride | 16 | $323 | $20 |
| Nystatin | 11 | $251 | $23 |
| Levofloxacin | 21 | $238 | $11 |
| Prednisone | 24 | $230 | $10 |
| Metronidazole | 13 | $190 | $15 |
| Gabapentin | 14 | $186 | $13 |
| Lorazepam | 32 | $179 | $6 |
| Azithromycin | 17 | $169 | $10 |
| Prochlorperazine Maleate | 24 | $120 | $5 |
| Pantoprazole | 19 | $114 | $6 |
| Cephalexin | 11 | $112 | $10 |
| Omeprazole | 11 | $75 | $7 |
2015: 23 drugs
| Revlimid | 73 | $697,429 | $9,554 |
| Imbruvica | 22 | $206,711 | $9,396 |
| Pomalyst | 12 | $143,865 | $11,989 |
| Promacta | 12 | $116,174 | $9,681 |
| Gleevec | 12 | $115,796 | $9,650 |
| Enoxaparin | 22 | $11,915 | $542 |
| Xarelto | 12 | $3,902 | $325 |
| Hydroxyurea | 75 | $1,975 | $26 |
| Warfarin | 113 | $1,887 | $17 |
| Exemestane | 11 | $1,882 | $171 |
| Hydrocodone-Acetaminophen | 40 | $953 | $24 |
| Acyclovir | 55 | $827 | $15 |
| Dexamethasone | 46 | $744 | $16 |
| Nystatin | 29 | $648 | $22 |
| Potassium Chloride | 21 | $509 | $24 |
| Megestrol Acetate | 12 | $315 | $26 |
| Gabapentin | 20 | $266 | $13 |
| Levothyroxine | 12 | $259 | $22 |
| Omeprazole | 21 | $237 | $11 |
| Levofloxacin | 17 | $196 | $12 |
| Prednisone | 18 | $127 | $7 |
| Lorazepam | 19 | $103 | $5 |
| Azithromycin | 11 | $82 | $7 |
2014: 20 drugs
| Revlimid | 102 | $943,413 | $9,249 |
| Enoxaparin | 13 | $12,245 | $942 |
| Hydroxyurea | 71 | $1,822 | $26 |
| Fluconazole | 21 | $1,697 | $81 |
| Acyclovir | 89 | $1,665 | $19 |
| Warfarin | 136 | $1,598 | $12 |
| Exemestane | 12 | $1,560 | $130 |
| Dexamethasone | 55 | $846 | $15 |
| Hydrocodone-Acetaminophen | 48 | $783 | $16 |
| Omeprazole | 42 | $477 | $11 |
| Nystatin | 19 | $447 | $24 |
| Levofloxacin | 24 | $439 | $18 |
| Pantoprazole | 29 | $435 | $15 |
| Ondansetron | 11 | $367 | $33 |
| Prednisone | 23 | $197 | $9 |
| Azithromycin | 21 | $167 | $8 |
| Lorazepam | 19 | $147 | $8 |
| Gabapentin | 11 | $120 | $11 |
| Amitriptyline | 12 | $72 | $6 |
| Amlodipine Besylate | 14 | $55 | $4 |
2013: 25 drugs
| Revlimid | 103 | $884,010 | $8,583 |
| Gleevec | 20 | $132,623 | $6,631 |
| Tasigna | 11 | $92,919 | $8,447 |
| Acyclovir | 102 | $2,295 | $23 |
| Exemestane | 11 | $2,164 | $197 |
| Hydroxyurea | 57 | $2,072 | $36 |
| Warfarin | 110 | $1,823 | $17 |
| Fluconazole | 31 | $1,604 | $52 |
| Ondansetron | 17 | $871 | $51 |
| Dexamethasone | 64 | $656 | $10 |
| Pantoprazole | 39 | $517 | $13 |
| Hydrocodone-Acetaminophen | 45 | $448 | $10 |
| Levofloxacin | 22 | $346 | $16 |
| Omeprazole | 25 | $257 | $10 |
| Methylphenidate | 11 | $206 | $19 |
| Azithromycin | 17 | $171 | $10 |
| Allopurinol | 19 | $143 | $8 |
| Metoprolol | 18 | $132 | $7 |
| Lorazepam | 19 | $110 | $6 |
| Prednisone | 12 | $98 | $8 |
| Simvastatin | 12 | $91 | $8 |
| Prochlorperazine Maleate | 11 | $87 | $8 |
| Amlodipine Besylate | 15 | $77 | $5 |
| Atenolol | 12 | $48 | $4 |
| Amitriptyline | 13 | $23 | $2 |
Money from drug and device companies
$164,984 in 2025
| 2025 | 52 | 349 | $144,068 | $164,984 |
| 2024 | 14 | 61 | $46,011 | $56,386 |
| 2023 | 12 | 58 | $53,083 | $59,789 |
| 2022 | 12 | 123 | $132,655 | $153,920 |
| 2021 | 11 | 66 | $71,378 | $79,547 |
| 2020 | 14 | 26 | $18,636 | $19,881 |
| 2019 | 23 | 100 | $41,320 | $49,418 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Rybrevant | $35,383 | 49 payments
|
| Abbvie | Venclexta | $33,806 | 36 payments
|
| Karyopharm Therapeutics | Xpovio | $26,808 | 19 payments
|
| Genmab U.S. | Epkinly | $14,707 | 20 payments
|
| Incyte | Monjuvi | $14,048 | 22 payments
|
| Novartis Pharmaceuticals | Kymriah | $13,115 | 11 payments
|
See all 342 published payments
| Syndax Pharmaceuticals | Paid to speak or teach · 2025-12-24 | Revuforj | $3,128 |
| Legend Biotech USA | Meals · 2025-12-22 | Carvykti | $24 |
| Syndax Pharmaceuticals | Meals · 2025-12-21 | None | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-18 | Reblozyl | $2 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-18 | Reblozyl | $30 |
| Abbvie | Paid to speak or teach · 2025-12-18 | Venclexta | $3,000 |
| Abbvie | Paid to speak or teach · 2025-12-18 | Epkinly | $3,000 |
| Syndax Pharmaceuticals | Paid to speak or teach · 2025-12-18 | Revuforj | $1,043 |
| BeOne Medicines USA | Meals · 2025-12-17 | Brukinsa | $24 |
| Abbvie | Travel · 2025-12-11 | Epkinly | $164 |
| Abbvie | Meals · 2025-12-11 | Epkinly | $41 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-11 | Tagrisso | $29 |
| Karyopharm Therapeutics | Honoraria · 2025-12-10 | Xpovio | $1,550 |
| Syndax Pharmaceuticals | Meals · 2025-12-09 | Revuforj | $148 |
| Kite Pharma | Meals · 2025-12-08 | Yescarta | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-04 | Opdivo | $33 |
| Abbvie | Meals · 2025-12-04 | Venclexta | $125 |
| Abbvie | Travel · 2025-12-04 | Venclexta | $251 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-03 | Ninlaro | $2 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-03 | Iclusig | $22 |
| Pfizer | Meals · 2025-12-03 | Ibrance | $35 |
| Jazz Pharmaceuticals | Meals · 2025-12-02 | Zepzelca | $37 |
| Agios Pharmaceuticals | Meals · 2025-12-01 | Pyrukynd | $24 |
| Abbvie | Meals · 2025-11-26 | Venclexta | $0 |
| Abbvie | Meals · 2025-11-25 | Epkinly | $25 |
| Abbvie | Meals · 2025-11-20 | Venclexta | $19 |
| Genzyme | Meals · 2025-11-19 | Sarclisa | $26 |
| Array Biopharma | Meals · 2025-11-18 | Braftovi | $24 |
| Incyte | Meals · 2025-11-17 | Zynyz | $25 |
| Merck Sharp & Dohme | Meals · 2025-11-13 | Keytruda | $32 |
| Janssen Biotech | Meals · 2025-11-12 | Darzalex | $54 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-11 | Ninlaro | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-11 | Iclusig | $21 |
| Pfizer | Meals · 2025-11-11 | Xtandi | $21 |
| Genmab U.S. | Consulting · 2025-11-08 | Epkinly | $1,950 |
| Genmab U.S. | Meals · 2025-11-08 | Epkinly | $41 |
| Genmab U.S. | Meals · 2025-11-08 | Epkinly | $102 |
| Genmab U.S. | Travel · 2025-11-08 | Epkinly | $22 |
| Merck Sharp & Dohme | Meals · 2025-11-06 | Keytruda | $30 |
| Janssen Biotech | Travel · 2025-11-05 | Rybrevant | $226 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-05 | Opdivo | $32 |
| GlaxoSmithKline | Meals · 2025-11-05 | Jemperli | $33 |
| Invivyd | Meals · 2025-11-05 | Pemgarda | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-04 | Opdivo | $21 |
| Sobi | Meals · 2025-11-03 | Vonjo | $36 |
| Pfizer | Meals · 2025-10-30 | Padcev | $35 |
| Karyopharm Therapeutics | Honoraria · 2025-10-30 | Xpovio | $3,875 |
| Karyopharm Therapeutics | Meals · 2025-10-30 | Xpovio | $123 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-29 | Ninlaro | $2 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-29 | Iclusig | $31 |
| Incyte | Paid to speak or teach · 2025-10-29 | Monjuvi | $2,200 |
| Genmab U.S. | Paid to speak or teach · 2025-10-29 | Epkinly | $600 |
| Merck Sharp & Dohme | Meals · 2025-10-27 | Keytruda | $25 |
| Tempus AI | Meals · 2025-10-27 | Xt Cdx | $18 |
| Janssen Biotech | Meals · 2025-10-23 | Erleada | $36 |
| Janssen Biotech | Paid to speak or teach · 2025-10-23 | Rybrevant | $2,860 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-23 | Enhertu | $22 |
| Incyte | Meals · 2025-10-23 | Monjuvi | $124 |
| Incyte | Travel · 2025-10-23 | Monjuvi | $13 |
| Janssen Biotech | Meals · 2025-10-22 | Rybrevant | $108 |
| Array Biopharma | Meals · 2025-10-21 | Lorbrena | $36 |
| Merck Sharp & Dohme | Meals · 2025-10-20 | Keytruda | $30 |
| Janssen Biotech | Paid to speak or teach · 2025-10-17 | Rybrevant | $880 |
| Janssen Biotech | Paid to speak or teach · 2025-10-16 | Rybrevant | $3,300 |
| Janssen Biotech | Travel · 2025-10-16 | Rybrevant | $234 |
| Ipsen Biopharmaceuticals | Meals · 2025-10-16 | Onivyde | $35 |
| Janssen Biotech | Meals · 2025-10-14 | Darzalex | $48 |
| Celgene | Meals · 2025-10-10 | Reblozyl | $1 |
| Celgene | Meals · 2025-10-10 | Reblozyl | $31 |
| Abbvie | Consulting · 2025-10-10 | Venclexta | $2,100 |
| Janssen Biotech | Meals · 2025-10-09 | Rybrevant | $116 |
| EMD Serono | Meals · 2025-10-08 | None | $22 |
| Gilead Sciences | Meals · 2025-10-07 | Trodelvy | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-06 | Opdivo | $18 |
| Abbvie | Consulting · 2025-10-01 | Epkinly | $3,600 |
| Abbvie | Travel · 2025-10-01 | Epkinly | $275 |
| Abbvie | Travel · 2025-10-01 | Epkinly | $779 |
| Abbvie | Travel · 2025-10-01 | Epkinly | $250 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-01 | None | $24 |
| Eisai | Meals · 2025-09-29 | Lenvima | $24 |
| Deciphera Pharmaceuticals | Meals · 2025-09-25 | Qinlock | $22 |
| Incyte | Paid to speak or teach · 2025-09-24 | Monjuvi | $2,200 |
| Genzyme | Meals · 2025-09-22 | Wayrilz | $38 |
| Abbvie | Paid to speak or teach · 2025-09-18 | Venclexta | $3,000 |
| Incyte | Meals · 2025-09-18 | Monjuvi | $74 |
| Incyte | Travel · 2025-09-18 | Monjuvi | $198 |
| BeOne Medicines USA | Meals · 2025-09-17 | Brukinsa | $24 |
| Kite Pharma | Meals · 2025-09-17 | Yescarta | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-15 | Imfinzi | $23 |
| Genmab U.S. | Paid to speak or teach · 2025-09-15 | Epkinly | $3,000 |
| Fennec Pharmaceuticals | Meals · 2025-09-15 | Fyarro | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-12 | Fruzaqla | $22 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-09-11 | None | $575 |
| Celgene | Meals · 2025-09-11 | Reblozyl | $22 |
| Abbvie | Travel · 2025-09-10 | Venclexta | $29 |
| Abbvie | Meals · 2025-09-10 | Venclexta | $125 |
| Alexion Pharmaceuticals | Meals · 2025-09-10 | Ultomiris | $28 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-10 | Ninlaro | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-10 | Iclusig | $30 |
| Genmab U.S. | Travel · 2025-09-09 | Epkinly | $84 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-08 | Opdivo | $20 |
| Abbvie | Meals · 2025-09-05 | Epkinly | $15 |
| Abbvie | Meals · 2025-09-05 | Epkinly | $115 |
| Janssen Biotech | Meals · 2025-09-04 | Darzalex | $34 |
| Tempus AI | Meals · 2025-09-03 | Xt Cdx | $16 |
| Invivyd | Consulting · 2025-08-29 | Pemgarda | $2,818 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-27 | Opdivo | $23 |
| Adc Therapeutics America | Meals · 2025-08-27 | Zynlonta | $22 |
| Jazz Pharmaceuticals | Meals · 2025-08-26 | Zepzelca | $35 |
| Celgene | Meals · 2025-08-25 | Reblozyl | $26 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-08-22 | None | $4,025 |
| Abbvie | Consulting · 2025-08-22 | Venclexta | $1,200 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-22 | Imfinzi | $28 |
| Janssen Biotech | Paid to speak or teach · 2025-08-21 | Rybrevant | $880 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-21 | Iclusig | $27 |
| Syndax Pharmaceuticals | Meals · 2025-08-20 | None | $21 |
| Array Biopharma | Meals · 2025-08-19 | Braftovi | $32 |
| Janssen Pharmaceuticals | Education · 2025-08-18 | None | $8 |
| Janssen Pharmaceuticals | Education · 2025-08-18 | None | $16 |
| Janssen Biotech | Meals · 2025-08-18 | Carvykti | $33 |
| Janssen Biotech | Paid to speak or teach · 2025-08-15 | Rybrevant | $3,300 |
| Janssen Biotech | Travel · 2025-08-15 | Rybrevant | $50 |
| Janssen Biotech | Travel · 2025-08-15 | Rybrevant | $902 |
| Janssen Biotech | Travel · 2025-08-14 | Rybrevant | $369 |
| Incyte | Meals · 2025-08-14 | Monjuvi | $25 |
| Janssen Biotech | Meals · 2025-08-13 | Rybrevant | $121 |
| Incyte | Meals · 2025-08-12 | Jakafi | $27 |
| Janssen Biotech | Travel · 2025-08-11 | Rybrevant | $6 |
| Janssen Biotech | Paid to speak or teach · 2025-08-08 | Rybrevant | $550 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-05 | Lynparza | $26 |
| Daiichi Sankyo | Meals · 2025-08-04 | Datroway | $28 |
| Janssen Biotech | Paid to speak or teach · 2025-08-01 | Rybrevant | $2,860 |
| Genmab U.S. | Paid to speak or teach · 2025-08-01 | Epkinly | $3,000 |
| Genmab U.S. | Meals · 2025-07-31 | Epkinly | $125 |
| Iovance Biotherapeutics | Meals · 2025-07-31 | Amtagvi | $23 |
| Janssen Biotech | Meals · 2025-07-30 | Rybrevant | $122 |
| Merck Sharp & Dohme | Meals · 2025-07-30 | Keytruda | $26 |
| Janssen Biotech | Paid to speak or teach · 2025-07-29 | Rybrevant | $2,860 |
| Novartis Pharmaceuticals | Meals · 2025-07-29 | Lutathera | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-28 | Tagrisso | $31 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-07-25 | Ninlaro | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-07-25 | Iclusig | $4 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-07-25 | Iclusig | $21 |
| Janssen Biotech | Meals · 2025-07-24 | Rybrevant | $110 |
| Abbvie | Paid to speak or teach · 2025-07-24 | Venclexta | $3,000 |
| Merck Sharp & Dohme | Meals · 2025-07-24 | Keytruda | $30 |
| Karyopharm Therapeutics | Meals · 2025-07-23 | Xpovio | $96 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-22 | Imfinzi | $22 |
| Array Biopharma | Meals · 2025-07-22 | Lorbrena | $25 |
| Incyte | Paid to speak or teach · 2025-07-17 | Monjuvi | $5,775 |
| Novartis Pharmaceuticals | Consulting · 2025-07-16 | Kymriah | $4,200 |
| Array Biopharma | Meals · 2025-07-16 | Lorbrena | $26 |
| Pfizer | Meals · 2025-07-16 | Xtandi | $19 |
| Abbvie | Travel · 2025-07-14 | Venclexta | $22 |
| Abbvie | Travel · 2025-07-14 | Venclexta | $19 |
| Abbvie | Meals · 2025-07-14 | Venclexta | $149 |
| Janssen Biotech | Travel · 2025-07-12 | Rybrevant | $99 |
| Janssen Biotech | Travel · 2025-07-12 | Rybrevant | $115 |
| Janssen Biotech | Meals · 2025-07-12 | Rybrevant | $48 |
| Abbvie | Consulting · 2025-07-10 | Venclexta | $600 |
| Merck Sharp & Dohme | Meals · 2025-07-10 | Keytruda | $28 |
| Incyte | Meals · 2025-07-09 | Monjuvi | $14 |
| Iovance Biotherapeutics | Meals · 2025-07-09 | Amtagvi | $29 |
| Rigel Pharmaceuticals | Meals · 2025-07-08 | Tavalisse | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-07 | Opdivo | $30 |
| Abbvie | Meals · 2025-07-03 | Venclexta | $15 |
| Janssen Biotech | Paid to speak or teach · 2025-07-02 | Rybrevant | $880 |
| Janssen Biotech | Paid to speak or teach · 2025-07-02 | Rybrevant | $1,650 |
| Janssen Biotech | Paid to speak or teach · 2025-07-02 | Rybrevant | $3,300 |
| Merck Sharp & Dohme | Meals · 2025-07-02 | Keytruda | $19 |
| Genmab U.S. | Meals · 2025-07-01 | Epkinly | $26 |
| Celgene | Meals · 2025-06-30 | Reblozyl | $1 |
| Celgene | Meals · 2025-06-30 | Reblozyl | $30 |
| Incyte | Meals · 2025-06-28 | Monjuvi | $30 |
| Incyte | Meals · 2025-06-28 | Monjuvi | $30 |
| Incyte | Meals · 2025-06-28 | Monjuvi | $60 |
| Incyte | Travel · 2025-06-28 | Monjuvi | $304 |
| Incyte | Meals · 2025-06-28 | Monjuvi | $60 |
| Incyte | Travel · 2025-06-28 | Monjuvi | $108 |
| Incyte | Travel · 2025-06-28 | Monjuvi | $1,371 |
| Incyte | Meals · 2025-06-27 | Monjuvi | $13 |
| Janssen Biotech | Meals · 2025-06-26 | Rybrevant | $27 |
| Janssen Biotech | Meals · 2025-06-26 | Rybrevant | $140 |
| Integra LifeSciences | Meals · 2025-06-26 | Omnigraft | $45 |
| Janssen Biotech | Meals · 2025-06-25 | Darzalex | $34 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-25 | None | $27 |
| Janssen Biotech | Travel · 2025-06-24 | Rybrevant | $708 |
| Abbvie | Meals · 2025-06-23 | Imbruvica | $17 |
| SpringWorks Therapeutics | Meals · 2025-06-23 | Gomekli | $28 |
| Lilly USA | Meals · 2025-06-19 | Verzenio | $24 |
| Eisai | Meals · 2025-06-19 | Lenvima | $24 |
| GlaxoSmithKline | Meals · 2025-06-18 | Jemperli | $32 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-06-18 | None | $23 |
| Novartis Pharmaceuticals | Consulting · 2025-06-17 | None | $2,100 |
| Karyopharm Therapeutics | Honoraria · 2025-06-17 | Xpovio | $3,875 |
| Karyopharm Therapeutics | Travel · 2025-06-17 | Xpovio | $218 |
| Karyopharm Therapeutics | Meals · 2025-06-17 | Xpovio | $119 |
| Genmab U.S. | Consulting · 2025-06-13 | Epkinly | $4,160 |
| Celgene | Meals · 2025-06-12 | Reblozyl | $27 |
| Merck Sharp & Dohme | Meals · 2025-06-10 | Keytruda | $34 |
| Array Biopharma | Meals · 2025-06-09 | Braftovi | $28 |
| Celgene | Meals · 2025-06-06 | Reblozyl | $32 |
| Celgene | Meals · 2025-06-06 | Reblozyl | $1 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-05 | Opdivo | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-05 | Opdivo | $1 |
| Janssen Biotech | Meals · 2025-06-04 | Rybrevant | $26 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-04 | Fruzaqla | $16 |
| Janssen Biotech | Travel · 2025-06-02 | Rybrevant | $317 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-02 | Ninlaro | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-02 | Iclusig | $26 |
| Incyte | Paid to speak or teach · 2025-05-30 | Monjuvi | $275 |
| Astellas Pharma US | Meals · 2025-05-29 | Vyloy | $20 |
| Integra LifeSciences | Meals · 2025-05-29 | Omnigraft | $68 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-28 | Opdivo | $21 |
| Pfizer | Meals · 2025-05-28 | Elrexfio | $7 |
| Agios Pharmaceuticals | Meals · 2025-05-21 | Pyrukynd | $32 |
| Janssen Biotech | Meals · 2025-05-20 | Carvykti | $31 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-05-19 | None | $575 |
| Genmab U.S. | Meals · 2025-05-17 | Epkinly | $25 |
| Genmab U.S. | Travel · 2025-05-17 | Epkinly | $47 |
| Genmab U.S. | Meals · 2025-05-17 | Epkinly | $50 |
| Genmab U.S. | Meals · 2025-05-17 | Epkinly | $35 |
| Genmab U.S. | Travel · 2025-05-17 | Epkinly | $68 |
| Abbvie | Paid to speak or teach · 2025-05-16 | Venclexta | $4,200 |
| Genmab U.S. | Travel · 2025-05-16 | Epkinly | $273 |
| Genmab U.S. | Travel · 2025-05-16 | Epkinly | $71 |
| Genmab U.S. | Travel · 2025-05-16 | Epkinly | $989 |
| Genmab U.S. | Travel · 2025-05-16 | Epkinly | $38 |
| Pfizer | Meals · 2025-05-15 | Xtandi | $16 |
| Janssen Biotech | Meals · 2025-05-14 | Darzalex | $25 |
| Karyopharm Therapeutics | Honoraria · 2025-05-14 | Xpovio | $3,875 |
| Karyopharm Therapeutics | Travel · 2025-05-14 | Xpovio | $117 |
| Karyopharm Therapeutics | Meals · 2025-05-14 | Xpovio | $120 |
| Pfizer | Meals · 2025-05-13 | Xtandi | $21 |
| Gilead Sciences | Meals · 2025-05-13 | Trodelvy | $24 |
| Sanofi US Services | Meals · 2025-05-12 | None | $20 |
| Genzyme | Meals · 2025-05-12 | None | $22 |
| Recordati Rare Diseases Inc. | Meals · 2025-05-07 | Enjaymo | $23 |
| SpringWorks Therapeutics | Meals · 2025-05-07 | Ogsiveo | $21 |
| Jazz Pharmaceuticals | Meals · 2025-05-06 | Ziihera | $29 |
| Kite Pharma | Consulting · 2025-05-04 | Yescarta | $9,470 |
| Kite Pharma | Meals · 2025-05-04 | Yescarta | $38 |
| Kite Pharma | Meals · 2025-05-04 | Yescarta | $53 |
| Kite Pharma | Meals · 2025-05-04 | Yescarta | $67 |
| Kite Pharma | Meals · 2025-05-03 | Yescarta | $17 |
| Kite Pharma | Meals · 2025-05-03 | Yescarta | $28 |
| Kite Pharma | Meals · 2025-05-03 | Yescarta | $58 |
| Kite Pharma | Meals · 2025-05-03 | Yescarta | $150 |
| Kite Pharma | Meals · 2025-05-02 | Yescarta | $127 |
| Kite Pharma | Travel · 2025-05-02 | Yescarta | $427 |
| Kite Pharma | Travel · 2025-05-02 | Yescarta | $527 |
| Novartis Pharmaceuticals | Meals · 2025-05-01 | Kymriah | $39 |
| Abbvie | Meals · 2025-04-30 | Venclexta | $122 |
| Abbvie | Travel · 2025-04-30 | Venclexta | $978 |
| Karyopharm Therapeutics | Honoraria · 2025-04-29 | Xpovio | $775 |
| Incyte | Consulting · 2025-04-28 | None | $1,100 |
| Merck Sharp & Dohme | Meals · 2025-04-28 | Keytruda | $31 |
| Iovance Biotherapeutics | Meals · 2025-04-24 | Amtagvi | $26 |
| GlaxoSmithKline | Meals · 2025-04-23 | Jemperli | $25 |
| Exelixis | Meals · 2025-04-21 | Cabometyx | $45 |
| Abbvie | Paid to speak or teach · 2025-04-18 | None | $3,000 |
| Janssen Biotech | Meals · 2025-04-17 | Darzalex | $15 |
| Agios Pharmaceuticals | Meals · 2025-04-17 | Pyrukynd | $45 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-16 | Opdivo | $41 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-16 | Ninlaro | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-16 | Iclusig | $22 |
| Array Biopharma | Meals · 2025-04-15 | Xalkori | $23 |
| Array Biopharma | Meals · 2025-04-15 | Xalkori | $4 |
| Karyopharm Therapeutics | Honoraria · 2025-04-15 | Xpovio | $3,875 |
| Karyopharm Therapeutics | Meals · 2025-04-15 | Xpovio | $122 |
| Karyopharm Therapeutics | Travel · 2025-04-15 | Xpovio | $27 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-14 | Opdivo | $1 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-14 | Opdivo | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-14 | Opdivo | $1 |
| Janssen Biotech | Travel · 2025-04-12 | Rybrevant | $25 |
| Janssen Biotech | Travel · 2025-04-12 | Rybrevant | $83 |
| Spectrum Pharmaceuticals | Meals · 2025-04-09 | Rolvedon | $31 |
| Janssen Biotech | Paid to speak or teach · 2025-04-08 | Rybrevant | $2,860 |
| Pfizer | Meals · 2025-04-07 | Ibrance | $28 |
| Janssen Biotech | Meals · 2025-04-03 | Rybrevant | $145 |
| Puma Biotechnology | Meals · 2025-04-03 | Nerlynx | $27 |
| Novartis Pharmaceuticals | Meals · 2025-03-29 | Kymriah | $102 |
| Novartis Pharmaceuticals | Meals · 2025-03-29 | Kymriah | $76 |
| Novartis Pharmaceuticals | Consulting · 2025-03-29 | Kymriah | $5,500 |
| Novartis Pharmaceuticals | Travel · 2025-03-29 | Kymriah | $163 |
| Novartis Pharmaceuticals | Travel · 2025-03-29 | Kymriah | $134 |
| Novartis Pharmaceuticals | Travel · 2025-03-29 | Kymriah | $734 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-28 | Ninlaro | $8 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-28 | Ninlaro | $13 |
| Syndax Pharmaceuticals | Meals · 2025-03-27 | None | $26 |
| Karyopharm Therapeutics | Meals · 2025-03-27 | Xpovio | $122 |
| Karyopharm Therapeutics | Honoraria · 2025-03-27 | Xpovio | $3,875 |
| Karyopharm Therapeutics | Travel · 2025-03-27 | Xpovio | $20 |
| BeOne Medicines USA | Meals · 2025-03-24 | Brukinsa | $21 |
| Janssen Biotech | Paid to speak or teach · 2025-03-21 | Rybrevant | $2,860 |
| Abbvie | Travel · 2025-03-21 | None | $219 |
| Abbvie | Meals · 2025-03-21 | None | $28 |
| Janssen Biotech | Meals · 2025-03-20 | Rybrevant | $129 |
| Celgene | Meals · 2025-03-20 | Reblozyl | $19 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-19 | None | $34 |
| Abbvie | Consulting · 2025-03-18 | Venclexta | $600 |
| Kite Pharma | Meals · 2025-03-18 | Yescarta | $6 |
| Kite Pharma | Meals · 2025-03-17 | Yescarta | $14 |
| Astellas Pharma US | Meals · 2025-03-17 | Vyloy | $21 |
| Janssen Biotech | Meals · 2025-03-12 | Darzalex | $18 |
| GlaxoSmithKline | Meals · 2025-03-11 | Jemperli | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-10 | Tagrisso | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-10 | Enhertu | $35 |
| PharmaEssentia USA | Meals · 2025-03-06 | Besremi | $29 |
| Aveo Pharmaceuticals | Meals · 2025-03-04 | Fotivda | $29 |
| Daiichi Sankyo | Meals · 2025-02-27 | Enhertu | $19 |
| Merck Sharp & Dohme | Meals · 2025-02-26 | Keytruda | $34 |
| Array Biopharma | Meals · 2025-02-25 | Braftovi | $20 |
| Janssen Biotech | Paid to speak or teach · 2025-02-21 | Rybrevant | $1,100 |
| Janssen Biotech | Paid to speak or teach · 2025-02-20 | Rybrevant | $660 |
| Array Biopharma | Meals · 2025-02-20 | Braftovi | $26 |
| Daiichi Sankyo | Meals · 2025-02-19 | Enhertu | $27 |
| Abbvie | Consulting · 2025-02-18 | Venclexta | $2,700 |
| Janssen Biotech | Meals · 2025-02-13 | Darzalex | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-13 | Imfinzi | $27 |
| Kyowa Kirin | Meals · 2025-02-12 | Poteligeo | $27 |
| Karyopharm Therapeutics | Honoraria · 2025-02-12 | Xpovio | $3,875 |
| Karyopharm Therapeutics | Meals · 2025-02-12 | Xpovio | $148 |
| Eisai | Meals · 2025-02-10 | Lenvima | $29 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-05 | Ninlaro | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-05 | Ninlaro | $21 |
| Novartis Pharmaceuticals | Meals · 2025-01-29 | Kisqali | $33 |
| Merck Sharp & Dohme | Meals · 2025-01-29 | Keytruda | $21 |
| Coherus Oncology | Meals · 2025-01-26 | Loqtorzi | $33 |
| Abbvie | Meals · 2025-01-23 | Imbruvica | $22 |
| Kite Pharma | Meals · 2025-01-22 | Yescarta | $1 |
| Kite Pharma | Meals · 2025-01-22 | Yescarta | $8 |
| Kite Pharma | Meals · 2025-01-22 | Yescarta | $9 |
| Merck Sharp & Dohme | Meals · 2025-01-22 | Keytruda | $33 |
| Celgene | Meals · 2025-01-16 | Reblozyl | $1 |
| Celgene | Meals · 2025-01-16 | Reblozyl | $29 |
| Merck Sharp & Dohme | Meals · 2025-01-16 | Keytruda | $18 |
| BeiGene USA | Meals · 2025-01-15 | Brukinsa | $24 |
| Array Biopharma | Meals · 2025-01-14 | Xalkori | $22 |
| Incyte | Meals · 2025-01-13 | Monjuvi | $23 |
| Jazz Pharmaceuticals | Meals · 2025-01-07 | Ziihera | $33 |
| Genentech USA | Meals · 2025-01-06 | Columvi | $29 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $56,386
| Abbvie | Venclexta | $17,955 | 23 payments
|
| Novartis Pharmaceuticals | Kymriah | $10,607 | 13 payments
|
| Karyopharm Therapeutics | Xpovio | $9,052 | 7 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $5,586 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $3,352 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | None | $2,425 | 2 payments
|
| BeiGene USA | Brukinsa | $2,275 | 1 payment
|
| Pfizer | Elrexfio | $2,160 | 4 payments
|
| Amgen | Blincyto | $2,058 | 1 payment
|
| Daiichi Sankyo | Enhertu | $525 | 1 payment
|
| ADC Therapeutics America | None | $161 | 1 payment
|
| Janssen Biotech | Carvykti | $121 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $86 | 1 payment
|
| Celgene | None | $24 | 1 payment
|
2023: $59,789
| Karyopharm Therapeutics | Xpovio | $25,776 | 15 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $15,044 | 12 payments
|
| Gilead Sciences | None | $4,011 | 6 payments
|
| Incyte | None | $3,663 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | None | $2,964 | 2 payments
|
| Genmab U.S. | Epkinly | $2,621 | 8 payments
|
| Amgen | Blincyto | $2,058 | 1 payment
|
| Daiichi Sankyo | None | $1,410 | 1 payment
|
| Janssen Scientific Affairs | Imbruvica | $1,363 | 1 payment
|
| AbbVie | Venclexta | $845 | 5 payments
|
| Seagen | Adcetris | $19 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $15 | 1 payment
|
2022: $153,920
| Karyopharm Therapeutics | Xpovio | $65,121 | 36 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $30,246 | 26 payments
|
| GlaxoSmithKline | Blenrep | $28,619 | 16 payments
|
| Abbvie | Venclexta | $12,069 | 18 payments
|
| ADC Therapeutics America | None | $10,411 | 8 payments
|
| BeiGene USA | None | $3,167 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Abecma | $1,660 | 1 payment
|
| Pfizer | Bosulif | $1,564 | 3 payments
|
| Janssen Biotech | Tecvayli | $1,004 | 6 payments
|
| Novartis Pharmaceuticals | Scemblix | $22 | 1 payment
|
| Amgen | Lumakras | $19 | 1 payment
|
| Myriad Genetic Laboratories | Precisetumor | $17 | 1 payment
|
2021: $79,547
| Karyopharm Therapeutics | Xpovio | $30,313 | 17 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $26,478 | 18 payments
|
| ADC Therapeutics America | None | $14,047 | 15 payments
|
| Incyte | None | $2,153 | 1 payment
|
| Pfizer | Inlyta | $1,847 | 8 payments
|
| Jazz Pharmaceuticals | Vyxeos | $1,500 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $1,245 | 1 payment
|
| Adaptive Biotechnologies | Clonoseq | $1,000 | 1 payment
|
| Celgene | Onureg | $885 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $54 | 2 payments
|
| GlaxoSmithKline | Blenrep | $26 | 1 payment
|
2020: $19,881
| Karyopharm Therapeutics | Xpovio | $8,156 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $5,973 | 6 payments
|
| Celgene | Inrebic | $2,430 | 2 payments
|
| BeiGene USA | Brukinsa | $1,650 | 1 payment
|
| Rigel Pharmaceuticals | Tavalisse | $1,000 | 1 payment
|
| BeiGene | Brukinsa | $450 | 1 payment
|
| Janssen Biotech | Darzalex | $43 | 2 payments
|
| Pfizer | Xalkori | $38 | 3 payments
|
| Amgen | Prolia | $33 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $25 | 1 payment
|
| Daiichi Sankyo | Injectafer | $23 | 1 payment
|
| AbbVie | Venclexta | $22 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $20 | 1 payment
|
| Kite Pharma | None | $17 | 1 payment
|
2019: $49,418
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $20,158 | 24 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $7,551 | 14 payments
|
| Janssen Biotech | Imbruvica | $5,795 | 17 payments
|
| Jazz Pharmaceuticals | None | $5,551 | 8 payments
|
| AbbVie | None | $4,800 | 1 payment
|
| Celgene | Pomalyst | $4,697 | 4 payments
|
| Novartis Pharmaceuticals | Rydapt | $226 | 3 payments
|
| Seattle Genetics | Adcetris | $94 | 2 payments
|
| Exelixis | Cabometyx | $92 | 2 payments
|
| Amgen | Kanjinti | $85 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $51 | 3 payments
|
| Pfizer | Bosulif | $50 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $43 | 3 payments
|
| Taiho Oncology | Lonsurf | $42 | 2 payments
|
| Agios Pharmaceuticals | Tibsovo | $34 | 2 payments
|
| Tesaro | Zejula | $26 | 1 payment
|
| Astellas Pharma US | Xospata | $22 | 1 payment
|
| Clovis Oncology | Rubraca | $21 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Vitrakvi | $19 | 1 payment
|
| Eisai | Lenvima | $18 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $15 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $15 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $13 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia · 2024 | Their institution | $135,761 |
| ABBVIE INC. · A Phase 3 Multicenter Randomized Open-Label Trial To Evaluate Safety and Efficacy of Epcoritamab in Combination With R-Chop Compared To R-Chop in Subjects With High-Risk Diffuse Large B-Cell Lymphoma · 2024 | Their institution | $104,557 |
| Novartis Pharmaceuticals Corporation · A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia · 2025 | Their institution | $78,236 |
| ABBVIE INC. · M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial To Evaluate Safety and Efficacy of Epcoritamab in Combination With R-Chop Compared To R-Chop in Subjects With High-Risk Diffuse Large B-Cell Lymphoma · 2025 | Their institution | $24,952 |
| Incyte Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Pi3kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis · 2022 | Their institution | $21,000 |
| Incyte Corporation · A Randomized, Double-Blind, Placebo-Controlled Study of the Pi3kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response To Ruxolitinib · 2022 | Their institution | $20,300 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With Or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma · 2022 | Their institution | $19,171 |
| ABBVIE INC. · A Phase 3, Multicenter, Randomized, Open-Label Trial To Evaluate Safety and Efficacy of Epcoritamab in Combination With R-Chop Compared To R-Chop in Subjects With High-Risk Diffuse Large B-Cell Lymphoma · 2024 | Their institution | $17,268 |
| ABBVIE INC. · Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) To Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (Epcore Fl-1) · 2024 | Their institution | $17,268 |
| ABBVIE INC. · Study Assessing Activity of Intravenous (IV) Abbv-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed Or Refractory Multiple Myeloma · 2024 | Their institution | $17,268 |
| ABBVIE INC. · A Phase 3 Multicenter Randomized Open-Label Trial To Evaluate Safety and Efficacy of Epcoritamab in Combination With R-Chop Compared To R-Chop in Subjects With High-Risk Diffuse Large B-Cell Lymphoma · 2025 | Their institution | $15,053 |
| Incyte Corporation · A Phase 2 Study of the Safety, Tolerability, and Efficacy of Incb050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis · 2019 | Their institution | $9,071 |
| Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloid/Lymphoid Neoplasms With Fgfr1 Rearrangement · 2020 | Their institution | $7,000 |
| ABBVIE INC. · A Phase 3, Randomized, Open-Label Study To Evaluate Safety and Efficacy of Epcoritamab in Combination With R-Chop Compared To R-Chop in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (Dlbcl) · 2024 | Their institution | $5,666 |
| Celgene Corporation · Celgene - Connect Mds/Aml · 2020 | Their institution | $4,875 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Open Label Trial of Lenalidomidedexamethasone With Or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma · 2019 | Their institution | $3,889 |
| Incyte Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Pi3kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis · 2024 | Their institution | $3,885 |
| Incyte Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Pi3kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis · 2025 | Their institution | $3,882 |
| Incyte Corporation · A Randomized, Double-Blind, Placebo-Controlled Study of the Pi3kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response To Ruxolitinib · 2024 | Their institution | $3,450 |
| Celgene Corporation · Celgene - Connect Mdsaml · 2019 | Their institution | $3,375 |
| Celgene Corporation · Connect Mds/Aml · 2021 | Their institution | $3,125 |
| Celgene Corporation · A Phase 3b Randomized Study of Lenalidomide (Cc-50 · 2021 | Their institution | $3,000 |
| Celgene Corporation · A Phase 3b Randomized Study of Lenalidomide (Cc-5013) Plus Rituximab Maintenance Therapy Followed By Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, Or Mantle Cell Lymphoma · 2023 | Their institution | $2,796 |
| Celgene Corporation · Connect Mds/Aml - Connect Myeloid: the Myelofibrosis (Mf), Myelodysplastic Syndromes (Mds) and Acute Myeloid Leukemia (Aml) Disease Registry: the Purpose of the Connect Myeloid Disease Registry Is To Provide Unique Insights Into Treatment Decisions and Tr · 2023 | Their institution | $2,625 |
| Celgene Corporation · Connect Mds/Aml - Connect Myeloid: the Myelofibrosis (Mf), Myelodysplastic Syndromes (Mds) and Acute Myeloid Leukemia (Aml) Disease Registry: the Purpose of the Connect Myeloid Disease Registry Is To Provide Unique Insights Into Treatment Decisions and Tr · 2022 | Their institution | $2,250 |
| Celgene Corporation · Connect Mm- the Multiple Myeloma Disease Registry (Os002982) · 2019 | Their institution | $2,250 |
| Celgene Corporation · Connect Myeloid: the Myelofibrosis (Mf), Myelodysplastic Syndromes (Mds) and Acute Myeloid Leukemia (Aml) Disease Registry. the Purpose of the Connect Myeloid Disease Registry Is To Provide Unique Insights Into Treatment Decisions and Treatment Patterns As They Relate To Clinical Outcomes of Patients With Myeloid Diseases in Routine Clinical Practice. · 2025 | Their institution | $1,875 |
| Celgene Corporation · Connect Mm- the Multiple Myeloma Disease Registry · 2021 | Their institution | $1,875 |
| Incyte Corporation · A Randomized, Double-Blind, Placebo-Controlled Study of the Pi3kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response To Ruxolitinib · 2023 | Their institution | $1,850 |
| Celgene Corporation · Celgene Connect Myeloid Disease Registry · 2024 | Their institution | $1,500 |
| Incyte Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Pi3kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis · 2023 | Their institution | $1,350 |
| Celgene Corporation · A Phase 3b Randomized Study of Lenalidomide (Cc-5013) Plus Rituximab Maintenance Therapy Followed By Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, Or Mantle Cell Lymphoma(Ca078-P10) (Cc-5013-Nhl-008) · 2019 | Their institution | $1,326 |
| Celgene Corporation · Celgene - Connect Mm · 2020 | Their institution | $1,145 |
| Celgene Corporation · A Phase 3b Randomized Study of Lenalidomide (Cc-50 · 2022 | Their institution | $910 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With Or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma · 2020 | Their institution | $900 |
| Celgene Corporation · A Phase 3b Randomized Study of Lenalidomide (Cc-5013) Plus Rituximab Maintenance Therapy Followed By Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, Or Mantle Cell Lymphoma(Ca078-P10) · 2020 | Their institution | $864 |
| Celgene Corporation · Celgene - Connect Cll · 2019 | Their institution | $750 |
| Celgene Corporation · Celgene - Connect Mm · 2019 | Their institution | $750 |
| Celgene Corporation · The Purpose of the Connect Myeloid Disease Registry Is To Provide Unique Insights Into Treatment Decisions and Treatment Patterns As They Relate To Clinical Outcomes of Patients With Myeloid Diseases in Routine Clinical Practice. · 2024 | Their institution | $750 |
| Celgene Corporation · Connect Mm- the Multiple Myeloma Disease Registry · 2023 | Their institution | $375 |
| E.R. Squibb & Sons, L.L.C. · Connect Mm the Multiple Myeloma Disease Registry · 2024 | Their institution | $375 |
| Celgene Corporation · Connect Mm- the Multiple Myeloma Disease Registry · 2022 | Their institution | $375 |
| AbbVie Inc. · A Phase 3, Randomized, Open-Label Study To Evaluate Safety and Efficacy of Epcoritamab in Combination With R-Chop Compared To R-Chop in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (Dlbcl) · 2023 | This clinician | $35 |
Professional record
- NPI
- 1104844174
- Licence
- MA 223551
- Group
- Epic Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 10470 Old Placerville Rd, Sacramento, CA, 95827
- NPI first listed
- 2006-07-18
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.